Yicura BioMed completes first closing of Series B financing led by Gobi Partners to advance ICVAX HIV immunotherapy and cancer pipeline.
Round Type
Series B
Investors
Description
Yicura BioMed, a clinical-stage immunotherapy company based in Hong Kong Science Park, announced the first closing of its Series B financing round led by Gobi Partners with participation from strategic investors in Wuxi and institutional investors from Hong Kong. The funding will advance the core product ICVAX for HIV treatment and accelerate development of immunotherapy programs for cancer. ICVAX has completed a Phase I clinical trial showing favorable safety and immunogenicity, with advancement to Phase II for efficacy evaluation. The company aims to develop platform technologies for precision therapies addressing unmet needs in infectious diseases, cancers, and inflammatory conditions.
Quick answer
Yicura BioMed raised an undisclosed amount in a Series B round, dated November 13, 2026. Investors: Gobi Partners.
- How much did Yicura BioMed raise?
- Yicura BioMed raised an undisclosed amount in a Series B round on November 13, 2026.
- Who invested in Yicura BioMed?
- Gobi Partners is named as investors in this round.
- What does Yicura BioMed do?
- Yicura BioMed is a clinical-stage immunotherapy company based in Hong Kong Science Park developing medicines for infectious diseases, cancers, and inflammatory diseases.
- Who are the decision-makers at Yicura BioMed?
- Fundz holds 1 contact at Yicura BioMed, including the Associate Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Yicura BioMed that raised within 45 days of this round, from Fundz verified event records.
- Commit Biologics raised $60M (Seed) on November 17, 2026.
- Seawolf Therapeutics raised $100M (Seed) on November 16, 2026.
- 201 Therapeutics raised $178K (Seed) on November 16, 2026.
- Lifeplex Science raised $5.3M (Series A) on November 13, 2026.
- Orakl Oncology raised $34M (Series A) on November 12, 2026.
- VectorY raised $83M on November 11, 2026.
Who to call at Yicura BioMed, and when
A new round usually means Yicura BioMed is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Yicura BioMed raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Yicura BioMed, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Yicura BioMed. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Yicura BioMed raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansYicura BioMed raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.